254. ポルフィリン症 Porphyria Clinical trials / Disease details
臨床試験数 : 72 / 薬物数 : 53 - (DrugBank : 16) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 35
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04402489 (ClinicalTrials.gov) | June 1, 2020 | 20/5/2020 | Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria | EPP;XLP | Drug: Placebo;Drug: MT-7117 Low Dose;Drug: MT-7117 High Dose | Mitsubishi Tanabe Pharma Development America, Inc. | NULL | Completed | 12 Years | 75 Years | All | 184 | Phase 3 | United States;Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;Finland |
| 2 | NCT03520036 (ClinicalTrials.gov) | July 5, 2018 | 23/4/2018 | Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria | A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria | Erythropoietic Protoporphyria (EPP) | Drug: MT-7117 low dose;Drug: MT-7117 high dose;Drug: Placebo | Mitsubishi Tanabe Pharma Development America, Inc. | NULL | Completed | 18 Years | 75 Years | All | 102 | Phase 2 | United States |